Herbs (Global Traditional) · European
Valeriana officinalis
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Valerian root (Valeriana officinalis) contains valerenic acid and isovalerenic acid that enhance GABA neurotransmitter activity in the brain. These compounds modulate GABA-A receptors to promote relaxation and improve sleep quality.
Valeriana officinalis is a perennial herb native to Europe and Asia, commonly known as valerian, with roots and rhizomes used medicinally. The plant extracts are typically obtained from dried roots using ethanol or water extraction methods, yielding preparations rich in valepotriates, volatile oils, and iridoids.
Clinical evidence includes multiple RCTs showing valerian's efficacy for tension-type headaches (PMID: 32523884), mild insomnia (PMID: 37899385), and postoperative cognitive protection (PMID: 25173770). A systematic review of 16 RCTs suggested sleep quality improvements but noted methodological limitations, while some studies found no benefit in severe insomnia cases (PMID: 18482867).
Clinically studied doses include: 530 mg extract capsules twice daily (1,060 mg total) for cognitive function; 300 mg concentrated extract 30 minutes before bedtime for sleep; standardized extracts targeting 0.8% valerenic acid for 1-2 months. Consult a healthcare provider before starting any new supplement.
Valerian root is not consumed as a food for macronutrient content; it is used exclusively as a medicinal herb. Its pharmacological value derives from its bioactive compound profile rather than nutritional macronutrients. **Key Bioactive Compounds:** • **Valerenic acid** (0.1–0.9% of dried root): principal sesquiterpene acid; primary anxiolytic and sedative compound acting as a positive allosteric modulator of GABA-A receptors (particularly β3 subunit). Bioavailability is moderate orally with hepatic first-pass metabolism. • **Acetoxyvalerenic acid** and **hydroxyvalerenic acid**: related sesquiterpenoids present at ~0.01–0.2%, contributing to GABAergic activity. • **Isovaleric acid** (~0.1–0.5%): short-chain fatty acid with mild sedative properties; responsible for characteristic odor. • **Valepotriates (iridoids)** — including valtrate, isovaltrate, and didrovaltrate (0.5–2.0% in fresh root, but highly unstable and largely degraded in dried/processed preparations): cytotoxic in vitro but poorly bioavailable; considered minimally active in finished products. • **Lignans** — including hydroxypinoresinol and pinoresinol (~0.01–0.1%): partial agonist activity at 5-HT1A serotonin receptors; may contribute to anxiolytic effects. • **Flavonoids** — including hesperidin, linarin (acacetin-7-O-rutinoside, ~0.02–0.1%), and 6-methylapigenin: linarin shows synergistic sedative activity with valerenic acid in animal models. • **Volatile oil / Essential oil** (0.3–2.1% of dried root): composed of bornyl acetate (~30–50% of oil), bornyl isovalerate, camphene, β-pinene, sesquiterpenes (including valeranone, valerenal, kessyl esters). Valeranone comprises approximately 1–15% of the essential oil. • **GABA** (gamma-aminobutyric acid): present in aqueous extracts at approximately 0.04–0.8 mg/g dried root; however, exogenous GABA has limited blood-brain barrier penetration, so its direct CNS contribution is debated. • **Glutamine**: detected at ~0.2–0.5 mg/g; may serve as a GABA precursor after enzymatic conversion. • **Alkaloids** (trace, ~0.01–0.05%): including actinidine and valerianine; minor contribution to overall activity. **Minerals (approximate, per dried root):** Potassium (~8–15 mg/g), calcium (~5–12 mg/g), magnesium (~2–4 mg/g), iron (~0.1–0.3 mg/g), manganese (~0.03–0.1 mg/g), zinc (~0.02–0.05 mg/g). These are present but not pharmacologically significant at typical dosing (300–900 mg root extract/day). **Fiber & Carbohydrates:** Dried root contains polysaccharides and crude fiber (~15–25% w/w), including starch and mucilage, but these are irrelevant at medicinal doses. **Standardization & Bioavailability Notes:** Commercial extracts are typically standardized to 0.8–1.0% valerenic acid (e.g., the widely studied extract LI 156). Hydroethanolic extracts (40–70% ethanol) optimize extraction of sesquiterpenic acids and volatile compounds. Valerenic acid shows peak plasma levels (Tmax) at approximately 1–2 hours post-ingestion with an elimination half-life of ~1.1 hours. Aqueous extracts retain more GABA and glutamine but fewer lipophilic terpenoids. The clinical effects are attributed to the synergistic action of multiple compound classes rather than any single constituent.
Valerenic acid and isovalerenic acid in valerian root bind to GABA-A receptors and inhibit GABA breakdown by blocking GABA transaminase enzyme. This increases GABAergic neurotransmission in the central nervous system, promoting sedative and anxiolytic effects. Additional compounds like hesperidin and linarin contribute to the herb's calming properties through adenosine receptor modulation.
Randomized controlled trials demonstrate valerian's efficacy for specific conditions with moderate evidence quality. An 88-participant RCT showed significant reductions in tension-type headache severity using HIT-6, HDI, and VAS scoring systems. A separate 80-participant RCT over 56 days demonstrated improved sleep efficiency and subjective sleep parameters in mild insomnia patients. Most studies use 300-900mg daily doses, though larger trials are needed to establish optimal dosing protocols.
Valerian is generally well-tolerated with mild side effects including drowsiness, dizziness, and occasional gastrointestinal upset. It may potentiate sedative medications including benzodiazepines, barbiturates, and alcohol due to shared GABA pathways. Valerian can interact with anesthesia and should be discontinued 2 weeks before surgery. Safety during pregnancy and breastfeeding is not established, so use should be avoided in these populations.
